COMP <GO>
HROW vs CTY // NET PROFIT MARGIN
Harrow Inc. (NASDAQ) VS. City Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: HROW 1
— CTY 1
■ METRIC PARITY
LAST: $29.99 (+2.04%) • MKT CAP: $1.12B
net-margins
-1.90%
LAST: $22.14 (+2.26%) • MKT CAP: $1.11B
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HROW VS. CTY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HROW | CTY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 42.90% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.82% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 11.20% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -1.90% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 36.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.67 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.5 | 61.6 | -23.06 | CTY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.12B | $1.11B | $9.9M | HROW | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HROW REV | CTY REV | HROW GROSS % | CTY GROSS % | HROW FCF | CTY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $272.3M | — | 75.1% | — | $43.0M | — |
| FY 2024 | $199.6M | — | 75.3% | — | -$23.8M | — |
| FY 2023 | $130.2M | — | — | — | $3.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HROW // BETA —
CTY // BETA —